Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
440
Trial Sponsor
Clinical Trial Start Date
2006
0Primary Completion Date
2009
0Study Completion Date
2009
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 20
Phase 30
Official Name
Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study0
Last Updated
June 15, 2012
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Other attributes
Intervention Treatment
Placebo0
Sildenafil0
Study summary
Prevalence of heart failure (HF) with left ventricular (LV) diastolic dysfunction and preserved ejection fraction (EF) (HFpEF) is increasing. Prognosis worsens with development of pulmonary vasoconstriction and hypertension (PH) and right ventricular (RV) failure. The investigators aimed at modulating pulmonary vascular tone and RV burden in HFpEF due to high blood pressure (HBP), by using the phosphodiesterase-5 (PDE5) inhibitor sildenafil.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
